Lytix Biopharma

[Amaru]

VERRICA

March 9, 2022, at 11:10 a.m. ET

42nd Annual Cowen Virtual Healthcare Conference

Click to view webcast

[TekBot]

Lytix Biopharma to present at the 6th Annual Next Gen Immuno-Oncology Congress, UK

Oslo, 11 March 2022. Lytix Biopharma – a clinical-stage company with an in situ vaccination technology platform – is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, today will deliver an oral presentation at the 6th Annual Next Gen Immuno-Oncology Congress, which is taking place in London, UK.

Rekdal will discuss the major challenges represented by tumor heterogeneity and how oncolytic molecules can address this challenge by inducing a strong and broad activation of the immune system.
…

Vis børsmeldingen

“Our in situ vaccination technology platform delivers molecules with the potential to solve one of the major hurdles in cancer treatment. We are grateful for being invited to this annual next gen immuno-oncology conference and to present our proposed solution to the problem of genetic heterogeneity in cancer immunotherapy”, says Dr. Øystein Rekdal.

Title: Addressing Tumor Heterogeneity with Oncolytic Molecules – an unsolved issue in Cancer
Date and time: Friday 11 March 2022 at 14.30-15.00 EST

For more information, please contact:
Øystein Rekdal, CEO: +47 975 73 358
Gjest Breistein, CFO: +47 952 60 512
Ole Peter Nordby, Head of IR: +47 412 87 179

About the Congress
The 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress will address the challenges and future directions in immuno-oncology research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress will also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress UK

Lytix Biopharma in brief
Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

Kilde

[TekBot]

Lytix Biopharma - Exercise of warrants

Oslo, Norway, March 15, 2022 – Lytix Biopharma AS (the Company), a clinical-stage company with an in situ vaccination technology platform, announces today that 1,329,306 warrants giving rights to 1,329,306 shares have been exercised by PBM LYT Holdings, LLC (“PBM LYT”), an affiliate of PBM Capital Group, LLC (“PBM”). Following the registration of the new shares pursuant to the exercise, the number of outstanding shares in Lytix Biopharma will be 40,068,319 shares. Reference is made to the warrants issued by the Company’s General Meeting on June 7, 2021 with a subscription price per share of NOK 0.1 and with an expiry date of June 6, 2022 (the “Warrants”).

In June 2021, Lytix Biopharma successfully completed a private placement and national offering, raising gross proceeds of approximately NOK 225 million. The private placement and national offering attracted strong interest from existing shareholders and new investors, both in Norway, Sweden, and the US. After the successful completion of the private placement and
…

Vis børsmeldingen

national offering, Lytix listed its shares on Euronext Growth Oslo. PBM LYT pre-committed for NOK 42.5 million in the private placement and was awarded warrants equal to 56.3 per cent of the number of shares subscribed for by PBM LYT. The precommitment by PBM LYT, was very important for the successful completion of the private placement, and thus the financing of the Company’s activities. Further, the Company held the opinion that PBM LYT, as a shareholder in the Company, would provide additional value to the Company given PBM’s broad contact network, experience and expertise in the biotech industry, as well as reputation and standing in the US capital markets.

For more information, please contact:
Øystein Rekdal, CEO: +47 975 73 358
Gjest Breistein, CFO: +47 952 60 512

Lytix in brief: Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

Kilde

[Amaru]

Spin-off fra Lytix: AMICOAT

– Markedet er på 50 milliarder - vi håper å ta en betydelig andel

[Kallep]

Er dette noko som Lytix fortsatt har eigarskap i?

[polygon]

Biotekaksjer

Ja, her er tydeligvis greia at de begge to har debutert på Twitter. Men samtidig er det veldig sannsynlig at hun nevner studien hun er med å leder med Lytix sin LTX-315 i dette foredraget hun skal holde på AACR sitt årsmøte om noen uker: https://www.abstractsonline.com/pp8/#!/10517/presentation/734

[Kallep]

Lite FOMO i Lytix om dagen. Verkar ikkje som om folket har trua på at Verrica melder om oppstart av Fase 2 studier for LTX-315 innan 1.april., og tilhøyrande utbetaling til Lytix. Blir spennande å sjå. Er jo ikkje så mange dagar igjen av Q1 2022.

[stone]

Takk for påminnelsen

[stone]

@Kallep

oppstart av Fase 2 studier for LTX-315 innan 1.april

Ser forresten det står med fotnote “Timing of trial may be subject to change.”

[Kallep]

Ja, det er jo ikkje sikkert dei finn ein pasient som passer før 1.april, men det er nok ikkje så lenge til det kjem ein gladmelding fra USA. Lytix er ein bra biotek-aksje om ein ikkje har det travelt. Dei har ting på stell, ryddig økonomi og leverer på guidingene sine. Selskapet er ikkje akkurat noko traderfavoritt men det gjer ikkje noko for meg.

[stone]

Litt av et volum i dag

[stone]

Verrica uttalte faktisk senest 2 mars at de forventet å starte fase 2 i Q1, så de kan vel få inn første pasient så snart de finner en passende og villig kandidat…

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial...

[stone]

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in...

[TekBot]

Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals Inc. triggered by first patient dosed with LTX-315

Oslo, Norway, April 05, 2022 – Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, notes that the first patient has been dosed in Verrica Pharmaceuticals Inc.’s Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (skin cancer). This triggers a USD 1 million milestone payment to Lytix in accordance with the licensing agreement between the parties.

Verrica Pharmaceuticals Inc (“Verrica”) has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology conditions.
…

Vis børsmeldingen

“We are delighted to see Verrica doses the first patient in its Phase II trial evaluating LTX-315 as a non-surgical treatment option for patients with basal cell carcinoma. Non-melanoma skin cancers, including basal cell and squamous cell carcinomas, are the most common form of cancer in the U.S., with over 5 million diagnoses each year, and there is a high unmet need for new treatments. We look forward to following the development of our novel oncolytic molecule as a potential new treatment for non-melanoma skin cancer,” said Øystein Rekdal, CEO of Lytix Biopharma.

LTX-315 is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle, and in August 2020, Lytix licensed LTX-315 to Verrica for the treatment of dermatologic oncology indications.

Under the terms of the agreement, Lytix is entitled to receive an upfront payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of up to USD 111 million, including the mentioned milestone. In addition, Lytix is entitled to receive tiered royalties based on worldwide annual sales. There are approximately 3-4 million patients diagnosed with basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options.

To view the full announcement from Verrica, please visit Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma - Verrica Pharmaceuticals
For information about Verrica’s clinical trial, please visit www.clinicaltrials.gov.
For more information about Verrica, please visit www.verrica.com.

For further information please contact:
Øystein Rekdal (CEO),
Telephone: +47 975 73 358
E-mail: Oystein.Rekdal@lytixbiopharma.com

About Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a U.S. based, healthcare-focused investment firm. For more information, visit www.lytixbiopharma.com.

About LTX-315
LTX-315 is a potential first-in-class oncolytic molecule administered directly into a tumor to induce immunogenic cell death, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. LTX-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase I/II oncology trials.

About in situ vaccination
In situ vaccination stimulates a patient’s immune system by injecting drugs with the ability to kill cancer cells straight into the tumor environment. Lytix Biopharma has applied this approach with its first-in-class oncolytic molecules, representing an alternative and unique approach to cancer vaccination. Importantly, this approach generates an immune response against a broad antigen repertoire without pre-identifying the antigens, which in turn can save considerable costs and valuable time.

Kilde

[stone]

Lite utslag på melding enda…

[Kallep]

Ja, men det begynner i det minste å bli litt volum… Til å vera Lytix i alle fall

Mykje “tru og håp” blandt biotek på Oslo Børs, mens Lytix som faktisk har deal med ein større amerikansk aktør går litt under radaren. Trur dette vil endre seg etter kvart som fleire får augene opp for denne juvelen.

[Kallep]

Ser ut som at det er nokon som seriøst ikkje vil ha denne opp. Dumpar aksjer til 10 kr når selskapet melder om positivt nytt og det er kjøparer 2 kr høgare skjønner eg lite av… Men kvar sin smak. Eg blir sittande og tar gjerne fleire billige aksjer.

[Longtrader]

Ja, prøvde en trade i dag.

Hva lærte vi etter det gikk rett i rødt.

Selv ikke cash deal løfter norsk bio tech. I give up.

Det ble da ikke en trade om dere lurer, men nok en rød long posisjon.

Så blir det spennende å følge med, ville det vært lurest å ta stopp loss med en gang. Svaret kommer ved en senere anledning.

La oss håpe det blir opptur😉

[orionen]

Lytix leverer på alt som vanlig til og med litt volum i dag. Kursen kommer når den kommer.

[Longtrader]

Eksistere det noen analyse på denne?

Potensialet ?

Ellers ser eg data forventes i 23/24 lenger oppe , som den viktigste infoen for meg - så lenge blir ikke den i min portefølje(tror eg)Rød eller blå.